340 results on '"Friedberg, J."'
Search Results
2. Targeted Therapeutics for Lymphoma: Using Biology to Inform Treatment
3. OA02.06 No Significant Difference in Survival Between Radical Surgery and Visceral-Sparing Approach for Malignant Mesothelioma
4. OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI‐INSTITUTION RETROSPECTIVE ANALYSIS
5. SWOG 2114: A RANDOMIZED PHASE II TRIAL OF CONSOLIDATION THERAPY FOLLOWING CD19 CAR T‐CELL TREATMENT FOR RELAPSED/REFRACTORY LARGE B‐CELL OR GRADE IIIB FOLLICULAR LYMPHOMA
6. Patient‐ versus clinician‐reported symptoms in the POLARIX study
7. A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016
8. Targeted Therapeutics for Lymphoma: Using Biology to Inform Treatment
9. EP07.01-001 Molecular Profiling Predicts Outcomes in Patients With Resected Malignant Pleural Mesothelioma
10. Abstract No. 42 Balloon-assisted lymphatic Lipiodol escape reduction (BALLER) adjunctive technique for thoracic duct embolization
11. S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1
12. P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL
13. Unmet needs in the first-line treatment of follicular lymphoma
14. EP.06G.17 A Clinical Conundrum: Lung Cancer in the Breast
15. Activity of idelalisib in high-risk follicular lymphoma with early relapse following front line immunochemotherapy: 223
16. OA04.02 Diaphragm and Phrenic Nerve Preservation During Lung-Sparing Surgery for Malignant Pleural Mesothelioma: The Impact on Patient Outcomes
17. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†
18. Venetoclax based combination therapy does not overcome poor outcomes in BTKi‐refractory mantle cell lymphoma: phase 2 trial of umbralisib, ublituximab, and venetoclax.
19. CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY.
20. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia
21. NEW PROGNOSTIC SCORE INCORPORATING MTV PREDICTS TREATMENT FAILURE IN ADVANCED HODGKIN LYMPHOMA
22. Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma
23. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices
24. High-dose therapy and stem cell transplantation in follicular lymphoma
25. An Intergroup Approach for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826.
26. Bortezomib and gemcitabine in relapsed or refractory Hodgkinʼs lymphoma
27. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma
28. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkinʼs lymphoma: CALGB 59804
29. Implant failure predictors in the posterior maxilla: a retrospective study of 274 consecutive implants
30. 21. New Immunological Principles: 115 RESULTS FROM A PHASE I/II STUDY OF GALIXIMAB (ANTICD80) IN COMBINATION WITH RITUXIMAB (ANTI-CD20) FOR RELAPSED OR REFRACTORY, FOLLICULAR NHL
31. Socio-economic status and surgery in children: myringotomies and tonsillectomies in Ontario, Canada, 1996–2000
32. P1.06-20 Malignant Pleural Mesothelioma: Survival Meta-Analysis from 15 Years of a Standard Systemic Therapy
33. MA05.10 Pembrolizumab in the Treatment of Patients with Malignant Pleural Mesothelioma Following Progression After Initial Chemotherapy
34. P1.06-14 Posterior Intercostal Lymph Node Positivity as a Prognostic Indicator of Overall Survival in Resectable Malignant Pleural Mesothelioma
35. P1.01-10 Stage III Non-Small Cell Lung Cancer Clinical Outcomes with Surgical Resection After Definitive Neoadjuvant Chemoradiotherapy
36. PHASE II/III STUDY OF R‐MINICHOP ± ORAL AZACITIDINE IN PARTICIPANTS AGE 75 YEARS OR OLDER WITH DIFFUSE LARGE B CELL AND RELATED LYMPHOMAS.
37. S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL.
38. Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY.
39. HIGH RATE OF MORBID CENTRAL LINE ASSOCIATED COMPLICATIONS DURING TREATMENT WITH DOSE-ADJUSTED R-EPOCH THERAPY FOR NON-HODGKIN LYMPHOMA
40. Surgery and intraoperative photodynamic therapy for thoracic malignancies
41. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
42. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma
43. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma
44. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
45. The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation
46. Patterns of Recurrence in Patients With Locally Advanced Non-Small Cell Lung Cancer (LANSCLC) Treated With Concurrent Chemoradiation (CRT) Followed by Surgery
47. Implications of Pathological Complete Response (pCR) at the Primary Tumor After Chemoradiation Therapy (CRT) Followed by Surgical Resection in Patients With Locally Advanced, Non-Small Cell Lung Cancer (LANSCLC)
48. Magnetic Resonance Imaging Brain Staging in Stage I-III Non-Small Cell Lung Cancer (NSCLC): Incidence and Clinicopathologic Factors in Asymptomatic Brain Metastases at Diagnosis
49. A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy (CT-RT) for Unresectable Stage IIIA/IIIB NSCLC: A Report of Toxicities and Clinical Response
50. Abstract B56: An immuno-gene therapy clinical trial evaluating in situ vaccination of malignant pleural mesothelioma with intrapleural delivery of adenovirus-interferon-alpha-2b in combination with chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.